A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
What is the purpose of this trial?
The purpose of this study is to determine which combination of Nivolumab plus either Rucaparib, Docetaxel, or Enzalutamide is the most effective in treating Castration-resistant Prostate Cancer that has spread
- Trial withBristol-Myers Squibb Research and Development
- Start Date09/26/2018
- End Date02/17/2020
- Last Updated12/04/2018
- Study HIC#2000022918